Literature DB >> 28684381

Treatment for the endocrine resistant breast cancer: Current options and future perspectives.

Chun-Yu Liu1, Chia-Yun Wu1, Karineh Petrossian2, Tzu-Ting Huang3, Ling-Ming Tseng4, Shiuan Chen5.   

Abstract

Endocrine resistance remains a challenge and an unmet need for managing hormone receptor-positive breast cancer. The mechanisms of endocrine resistance are multifaceted and are likely to evolve over time following various single or combination therapies. The purpose of this review article is to provide general understanding of molecular basis of endocrine resistance of breast cancer and to offer comprehensive review on current treatment options and potential new treatment strategies for endocrine resistant breast cancers. Last but not the least, we discuss current challenges and future directions for management of endocrine resistant breast cancers.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Endocrine resistance; Estrogen receptor; Hormone receptor

Mesh：

Substances：

Year:  2017        PMID： 28684381     DOI： 10.1016/j.jsbmb.2017.07.001

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN： 0960-0760            Impact factor:   4.292


  18 in total

Review 1.  Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.

Authors:  Jin Zhang; Qianying Wang; Qing Wang; Jiangran Cao; Jiafu Sun; Zhengmao Zhu
Journal:  Cell Mol Life Sci       Date:  2019-08-30       Impact factor: 9.261

Review 2.  Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Authors:  Caroline E McCoach; Trever G Bivona
Journal:  Cancer Discov       Date:  2019-04-16       Impact factor: 39.397

3.  Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.

Authors:  Dan Lyu; Binliang Liu; Bo Lan; Xiaoying Sun; Lixi Li; Jingtong Zhai; Haili Qian; Fei Ma
Journal:  Chin J Cancer Res       Date:  2022-08-30       Impact factor: 4.026

4.  Using an Improved Residual Network to Identify PIK3CA Mutation Status in Breast Cancer on Ultrasound Image.

Authors:  Wen-Qian Shen; Yanhui Guo; Wan-Er Ru; Cheukfai Li; Guo-Chun Zhang; Ning Liao; Guo-Qing Du
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

5.  First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.

Authors:  Anna Hester; Franziska Henze; Christiane Travi; Nadia Harbeck; Rachel Wuerstlein
Journal:  Breast Care (Basel)       Date:  2021-03-15       Impact factor: 2.860

6.  INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

Authors:  Samuel J Rodgers; Lisa M Ooms; Viola M J Oorschot; Ralf B Schittenhelm; Elizabeth V Nguyen; Sabryn A Hamila; Natalie Rynkiewicz; Rajendra Gurung; Matthew J Eramo; Absorn Sriratana; Clare G Fedele; Franco Caramia; Sherene Loi; Genevieve Kerr; Helen E Abud; Georg Ramm; Antonella Papa; Andrew M Ellisdon; Roger J Daly; Catriona A McLean; Christina A Mitchell
Journal:  Nat Commun       Date:  2021-05-25       Impact factor: 14.919

7.  Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein.

Authors:  Li-Juan Deng; Ming Qi; Qun-Long Peng; Min-Feng Chen; Qi Qi; Jia-Yan Zhang; Nan Yao; Mao-Hua Huang; Xiao-Bo Li; Yin-Hui Peng; Jun-Shan Liu; Deng-Rui Fu; Jia-Xu Chen; Wen-Cai Ye; Dong-Mei Zhang
Journal:  Cancer Cell Int       Date:  2018-12-18       Impact factor: 5.722

8.  Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells.

Authors:  Junfeng Shi; Yi Chen; Wenxing Chen; Cuiju Tang; Honghong Zhang; Yuetong Chen; Xiuwei Yang; Zhi Xu; Jingsun Wei; Jinfei Chen
Journal:  J Cell Mol Med       Date:  2018-09-04       Impact factor: 5.310

9.  AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.

Authors:  Lu Cao; Cong Xu; Guomin Xiang; Fang Liu; Xiaozhen Liu; Congying Li; Jing Liu; Qingxiang Meng; Jiao Jiao; Yun Niu
Journal:  Mol Cancer       Date:  2018-09-14       Impact factor: 27.401

Review 10.  The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?

Authors:  David E Moulder; Diana Hatoum; Enoch Tay; Yiguang Lin; Eileen M McGowan
Journal:  Cancers (Basel)       Date:  2018-06-08       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.